Key Decisions for Cell and Gene Therapy Trials

This guide outlines three critical decisions that sponsors of cell and gene therapy (CAGT) trials must make early in the drug development process. It emphasizes the importance of identifying and engaging rare patient populations, which can be challenging due to the need for genetic screening and specific inclusion criteria. The guide details strategies for overcoming these challenges, such as creating dedicated patient registries and collaborating with patient advocacy groups. Additionally, it discusses the necessity of comprehensive laboratory assessments throughout the CAGT product lifecycle, highlighting the role of central labs and clinical research organizations in ensuring timely and accurate testing. The document also addresses evolving regulatory guidance, noting recent updates from the FDA and the importance of harmonizing global regulatory frameworks to facilitate the approval of new therapies. Overall, the guide stresses the need for early decision-making to enhance the likelihood of successful CAGT development and patient access to innovative therapies.